EOG Resources completes $5.6 billion acquisition of Encino Acquisition Partners
NEW YORK - Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a micro-cap pharmaceutical company with a market capitalization of $2.09 million, has announced its development of a software-as-a-Medical Device (SaMD) platform aimed at assisting pharmaceutical companies with the transition of prescription medications to over-the-counter (OTC) availability. This move aligns with the recent Executive Order by President Trump, aimed at lowering drug prices and expanding consumer access to medication. According to InvestingPro data, the company faces significant financial challenges, with revenue declining 12.2% over the last twelve months to $5.11 million.
The platform, which is designed to conform with FDA guidance, is intended to provide services including patient self-selection tools, integration with electronic health records, potential links with retail pharmacies, and robust cybersecurity and privacy measures. This technology is developed in response to the FDA’s newly approved guidance on the Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU), which outlines the process for Rx-to-OTC switches. InvestingPro analysis reveals the company operates with a weak financial health score of 1.57, indicating significant operational challenges ahead.
Petros’ President and Chief Commercial Officer, Fady Boctor, stated that the company’s efforts closely support the intention of the Executive Order and that the advancement of their platform could lead to significant partnership opportunities within the pharmaceutical industry.
In addition to the platform development, Petros also announced a reverse stock split of its common stock at a ratio of 1-for-25, effective at the close of business on Wednesday, April 30, 2025. The reverse stock split was authorized by the company’s stockholders at the annual meeting on November 20, 2024. The split-adjusted trading on the Nasdaq Capital Market will commence on Thursday, May 1, 2025, under the unchanged ticker "PTPI".
The reverse stock split aims to reduce the number of outstanding shares from approximately 53.5 million to around 2.1 million, without changing stockholders’ percentage interest in the company, except for adjustments due to rounding of fractional shares.
Petros Pharmaceuticals specializes in expanding consumer access to medication through OTC drug development programs and is actively developing a proprietary SaaS platform to facilitate the Rx-to-OTC conversion process, which could potentially benefit conditions such as erectile dysfunction and high cholesterol.
This news is based on a press release statement from Petros Pharmaceuticals, Inc. The company cautions that forward-looking statements in the press release are not guarantees of future performance and are subject to various risks and uncertainties.
In other recent news, Petros Pharmaceuticals has announced several key developments. The company is facing potential delisting from The Nasdaq Stock Market due to not meeting the minimum stockholders’ equity requirement. In response, Petros held a special meeting where stockholders approved significant changes to its equity structure, including increasing authorized shares and a potential reverse stock split. Additionally, Petros has engaged CBIZ CPAs as its new auditor following the acquisition of its previous auditor’s attest business. The company also reported promising results from an AI-assisted study aimed at facilitating the switch of prescription drugs to over-the-counter status, meeting FDA comprehension requirements.
Petros is advancing its AI-driven platform to enhance the Rx-to-OTC switch process, partnering with a big data firm to improve its identification verification system. This collaboration aligns with recent FDA guidance and aims to strengthen Petros’ position in the self-care market. Furthermore, Petros has priced a public stock offering at $0.24 per share, expecting to raise approximately $9.6 million in gross proceeds. The funds are intended for working capital and general corporate purposes. These developments underscore Petros Pharmaceuticals’ strategic efforts to maintain compliance, innovate in the self-care space, and secure financial stability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.